• Developing a pipeline of small molecule inhibitors of FAK, a validated cancer target
• Ongoing Phase 2a ACCENT trial in pancreatic cancer has achieved superiority over chemotherapy alone
• Undertaking a capital raising of $27.5 million to advance Narmafotinib and other opportunities

Amplia Therapeutics is developing a pipeline of small molecule inhibitors targeting Focal Adhesion Kinase (FAK), a validated cancer target. The company's lead compound, Narmafotinib, is the best-in-class FAK inhibitor in development and has shown promising clinical safety and tolerability, positioning it as a preferred agent to enhance the activity of drugs for the treatment of pancreatic cancer and other solid tumours. The ongoing Phase 1b/2a ACCENT trial is evaluating Narmafotinib in combination with the chemotherapies gemcitabine and Abraxane in patients with advanced pancreatic cancer. Positive interim data released in May 2025 showed that Narmafotinib is well tolerated and has promising efficacy materially exceeding the current standard of care, with 17 confirmed partial responses recorded. The trial has also achieved rare pathological complete responses and complete responses in advanced pancreatic cancer. Amplia is now undertaking a capital raising of $27.5 million via a two-tranche placement and share purchase plan to advance Narmafotinib and other opportunities, including combination trials with kRAS inhibitors and in ovarian cancer. The company expects a strong period of upcoming news flow, including top-line data from the ACCENT trial in late July/early August 2025 and the commencement of the Amplicity trial and other new studies in 2026.

Amplia expects to be funded into 2027 following the capital raising. The company has not provided any specific forward-looking financial metrics or guidance.